Phase III Flop Narrows Odds On Targacept Antidepressant, But Three Trials Remain
This article was originally published in Pharmaceutical Approvals Monthly
Nicotinic receptor company Targacept and TC-5214 partner AstraZeneca remain committed to a 2H 2012 filing of the drug as adjunct therapy for major depressive disorder.
You may also be interested in...
With achievement of milestones, deal could yield $1.24 billion for Phase IIb antidepressant.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.